CC BY-NC-ND 4.0 · Joints 2017; 05(01): 002-006
DOI: 10.1055/s-0037-1601405
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Single Platelet-Rich Plasma Injection for Early Stage of Osteoarthritis of the Knee

Liborio Ingala Martini
1   IRCCS Policlinico San Donato, Milan, Italy
Alessio Giai Via
1   IRCCS Policlinico San Donato, Milan, Italy
Chiara Fossati
1   IRCCS Policlinico San Donato, Milan, Italy
Filippo Randelli
1   IRCCS Policlinico San Donato, Milan, Italy
Pietro Randelli
1   IRCCS Policlinico San Donato, Milan, Italy
Davide Cucchi
1   IRCCS Policlinico San Donato, Milan, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
05 June 2017 (online)


Purpose The purpose of this study was to determine the safety efficacy and outcomes of platelet-rich plasma (PRP) intra-articular injections for early stages of knee osteoarthritis (OA).

Methods Twenty-five patients affected by grade I and II knee primary OA according to the Kellgren–Lawrence scale received a single intra-articular PRP injection. Patients were prospectively evaluated for 6 months. Visual analog scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Knee injury and Osteoarthritis Outcome Score (KOOS) scoring scales were used to evaluate clinical outcomes. Wilcoxon signed rank test was used to evaluate significance of improvement of WOMAC, KOOS, and VAS scores.

Results Twenty-one patients completed 6-months follow-up. The median WOMAC score improved from 29.1 points (range: 17.4–60.4; standard deviation [SD] = 13.0) at baseline to 42.41 (range: 24.3–71.2; SD = 12.5) at final follow-up. Improvements in median KOOS and VAS score have been also found, from 37.49 points and 64.2 mm before injection to 59.71 points and 42.8 mm, respectively. All these improvements were statistically significant (p < 0.05). No adverse reactions have been observed.

Conclusion Treating knee OA with PRP injection is safe. A single dose of PRP seems to be effective in managing pain and improving quality of life in patients with low-grade knee OA.

Level of Evidence Level IV, therapeutic case series.

  • References

  • 1 Barbour KE, Helmick CG, Theis KA. , et al; Centers for Disease Control and Prevention (CDC). Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation--United States, 2010-2012. MMWR Morb Mortal Wkly Rep 2013; 62 (44) 869-873
  • 2 Al-Arfaj A, Al-Boukai AA. Prevalence of radiographic knee osteoarthritis in Saudi Arabia. Clin Rheumatol 2002; 21 (02) 142-145
  • 3 Heijink A, Gomoll AH, Madry H. , et al. Biomechanical considerations in the pathogenesis of osteoarthritis of the knee. Knee Surg Sports Traumatol Arthrosc 2012; 20 (03) 423-435
  • 4 Kim HA, Kim S, Seo YI. , et al. The epidemiology of total knee replacement in South Korea: national registry data. Rheumatology (Oxford) 2008; 47 (01) 88-91
  • 5 Buckwalter JA, Martin JA, Brown TD. Perspectives on chondrocyte mechanobiology and osteoarthritis. Biorheology 2006; 43 (3-4): 603-609
  • 6 Monibi F, Roller BL, Stoker A, Garner B, Bal S, Cook JL. Identification of synovial fluid biomarkers for knee osteoarthritis and correlation with radiographic assessment. J Knee Surg 2016; 29 (03) 242-247
  • 7 Filardo G, Kon E, Di Martino A. , et al. Platelet-rich plasma vs hyaluronic acid to treat knee degenerative pathology: study design and preliminary results of a randomized controlled trial. BMC Musculoskelet Disord 2012; 13: 229 . Doi: 10.1186/1471-2474-13-229
  • 8 Cole BJ, Seroyer ST, Filardo G, Bajaj S, Fortier LA. Platelet-rich plasma: where are we now and where are we going?. Sports Health 2010; 2 (03) 203-210
  • 9 Beitzel K, McCarthy MB, Russell RP, Apostolakos J, Cote MP, Mazzocca AD. Learning about PRP using cell-based models. Muscles Ligaments Tendons J 2014; 4 (01) 38-45
  • 10 Wang F, He X. Intra-articular hyaluronic acid and corticosteroids in the treatment of knee osteoarthritis: a meta-analysis. Exp Ther Med 2015; 9 (02) 493-500
  • 11 Pollard B, Johnston M, Dixon D. Exploring differential item functioning in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). BMC Musculoskelet Disord 2012; 13: 265 . Doi: 10.1186/1471-2474-13-265
  • 12 Roos EM, Lohmander LS. The Knee injury and Osteoarthritis Outcome Score (KOOS): from joint injury to osteoarthritis. Health Qual Life Outcomes 2003; 1: 64 . Doi: 10.1186/1477-7525-1-64
  • 13 DeLoach LJ, Higgins MS, Caplan AB, Stiff JL. The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth Analg 1998; 86 (01) 102-106
  • 14 Neogi T. The epidemiology and impact of pain in osteoarthritis. Osteoarthritis Cartilage 2013; 21 (09) 1145-1153
  • 15 Raeissadat SA, Rayegani SM, Hassanabadi H. , et al. Knee osteoarthritis injection choices: platelet- rich plasma (PRP) versus hyaluronic acid (a one-year randomized clinical trial). Clin Med Insights Arthritis Musculoskelet Disord 2015; 8: 1-8
  • 16 Hsu WK, Mishra A, Rodeo SR. , et al. Platelet-rich plasma in orthopaedic applications: evidence-based recommendations for treatment. J Am Acad Orthop Surg 2013; 21 (12) 739-748
  • 17 Tarantino U, Ferlosio A, Arcuri G, Spagnoli LG, Orlandi A. Transglutaminase 2 as a biomarker of osteoarthritis: an update. Amino Acids 2013; 44 (01) 199-207
  • 18 Goldring MB, Goldring SR. Articular cartilage and subchondral bone in the pathogenesis of osteoarthritis. Ann N Y Acad Sci 2010; 1192: 230-237
  • 19 Söder S, Hakimiyan A, Rueger DC, Kuettner KE, Aigner T, Chubinskaya S. Antisense inhibition of osteogenic protein 1 disturbs human articular cartilage integrity. Arthritis Rheum 2005; 52 (02) 468-478
  • 20 Orlandi A, Oliva F, Taurisano G. , et al. Transglutaminase-2 differently regulates cartilage destruction and osteophyte formation in a surgical model of osteoarthritis. Amino Acids 2009; 36 (04) 755-763
  • 21 Via AG, De Cupis M, Spoliti M, Oliva F. Clinical and biological aspects of rotator cuff tears. Muscles Ligaments Tendons J 2013; 3 (02) 70-79
  • 22 Rosenthal AK, Gohr CM, Henry LA, Le M. Participation of transglutaminase in the activation of latent transforming growth factor beta1 in aging articular cartilage. Arthritis Rheum 2000; 43 (08) 1729-1733
  • 23 Scharstuhl A, Glansbeek HL, van Beuningen HM, Vitters EL, van der Kraan PM, van den Berg WB. Inhibition of endogenous TGF-beta during experimental osteoarthritis prevents osteophyte formation and impairs cartilage repair. J Immunol 2002; 169 (01) 507-514
  • 24 Johnson K, Hashimoto S, Lotz M, Pritzker K, Terkeltaub R. Interleukin-1 induces pro-mineralizing activity of cartilage tissue transglutaminase and factor XIIIa. Am J Pathol 2001; 159 (01) 149-163
  • 25 Alsousou J, Thompson M, Hulley P, Noble A, Willett K. The biology of platelet-rich plasma and its application in trauma and orthopaedic surgery: a review of the literature. J Bone Joint Surg Br 2009; 91 (08) 987-996
  • 26 El-Sharkawy H, Kantarci A, Deady J. , et al. Platelet-rich plasma: growth factors and pro- and anti-inflammatory properties. J Periodontol 2007; 78 (04) 661-669
  • 27 Mazzocca AD, McCarthy MB, Intravia J. , et al. An in vitro evaluation of the anti-inflammatory effects of platelet-rich plasma, ketorolac, and methylprednisolone. Arthroscopy 2013; 29 (04) 675-683
  • 28 Sundman EA, Cole BJ, Karas V. , et al. The anti-inflammatory and matrix restorative mechanisms of platelet-rich plasma in osteoarthritis. Am J Sports Med 2014; 42 (01) 35-41
  • 29 Dohan Ehrenfest DM, Andia I, Zumstein MA, Zhang CQ, Pinto NR, Bielecki T. Classification of platelet concentrates (Platelet-Rich Plasma-PRP, Platelet-Rich Fibrin-PRF) for topical and infiltrative use in orthopedic and sports medicine: current consensus, clinical implications and perspectives. Muscles Ligaments Tendons J 2014; 4 (01) 3-9
  • 30 Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol 2009; 27 (03) 158-167
  • 31 McCarrel TM, Minas T, Fortier LA. Optimization of leukocyte concentration in platelet-rich plasma for the treatment of tendinopathy. J Bone Joint Surg Am 2012; 94 (19) e143 , 1–8
  • 32 Mishra A, Randelli P, Barr C, Talamonti T, Ragone V, Cabitza P. Platelet-rich plasma and the upper extremity. Hand Clin 2012; 28 (04) 481-491
  • 33 Crane D, Everts P. Platelet rich plasma (PRP) matrix grafts. Pract Pain Manag 2008; 8: 12-26
  • 34 Andia I, Maffulli N. Platelet-rich plasma for managing pain and inflammation in osteoarthritis. Nat Rev Rheumatol 2013; 9 (12) 721-730
  • 35 Lai LP, Stitik TP, Foye PM, Georgy JS, Patibanda V, Chen B. Use of platelet rich plasma in intra-articular knee injections for osteoarthritis: a Systematic review. PM R 2015; 7 (06) 637-648
  • 36 Cerza F, Carnì S, Carcangiu A. , et al. Comparison between hyaluronic acid and platelet-rich plasma, intra-articular infiltration in the treatment of gonarthrosis. Am J Sports Med 2012; 40 (12) 2822-2827
  • 37 Patel S, Dhillon MS, Aggarwal S, Marwaha N, Jain A. Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: a prospective, double-blind, randomized trial. Am J Sports Med 2013; 41 (02) 356-364
  • 38 Zhu Y, Yuan M, Meng HY. , et al. Basic science and clinical application of platelet-rich plasma for cartilage defects and osteoarthritis: a review. Osteoarthritis Cartilage 2013; 21 (11) 1627-1637
  • 39 Ayhan E, Kesmezacar H, Akgun I. Intraarticular injections (corticosteroid, hyaluronic acid, platelet rich plasma) for the knee osteoarthritis. World J Orthop 2014; 5 (03) 351-361